2002
DOI: 10.15807/jorsj.45.385
|View full text |Cite
|
Sign up to set email alerts
|

REAL OPTIONS AND THE EVALUATION OF RESEARCH AND DEVELOPEMENT PROJECTS IN THE PHARMACEUTICAL INDUSTRY : A CASE STUDY(Special Issue on Theory, Methodology and Applications in Financial Engneering)

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2005
2005
2019
2019

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(1 citation statement)
references
References 10 publications
0
1
0
Order By: Relevance
“…In particular, they consider the case of Nihon Schering, which once their drug Y (the name used for convenience) gets the approval from the government, is allowed to undertake further research at a future time for developing other drugs similar to Y. Trang et al (2002) assume that the total cash inflow resulting from the growth opportunity is equal to a certain fraction of the total cash inflow due to drug Y, while the cost of the investment to be made at the time is equal to . The volatility of the project is assumed to be equal to 35%.…”
Section: Real Option Pricing Under Stochastic Interest Ratesmentioning
confidence: 99%
“…In particular, they consider the case of Nihon Schering, which once their drug Y (the name used for convenience) gets the approval from the government, is allowed to undertake further research at a future time for developing other drugs similar to Y. Trang et al (2002) assume that the total cash inflow resulting from the growth opportunity is equal to a certain fraction of the total cash inflow due to drug Y, while the cost of the investment to be made at the time is equal to . The volatility of the project is assumed to be equal to 35%.…”
Section: Real Option Pricing Under Stochastic Interest Ratesmentioning
confidence: 99%